SUBJECTS : Immunology | Immunotherapy | Immune System | Therapeutic Vaccine
Immunotherapy Advances: 2023, vol: 3, issue: 1
- 1)- A K Daramola, O A Akinrinmade, E A Fajemisin, K Naran, N Mthembu, S Hadebe, F Brombacher, A M Huysamen, O E Fadeyi, R Hunter, S Barth. A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG hybridomas in comparison to its recombinant allergen-drug conjugate. Immunotherapy advances. 2023, 3 (1): ltac023
Cited : 0Read More - 2)- Lucia Silla. Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances. 2023, 3 (1): ltac024Cited : 0Read More
- 3)- Natalie M Edner, Elisavet Ntavli, Lina Petersone, Chun Jing Wang, Astrid Fabri, Alexandros Kogimtzis, Vitalijs Ovcinnikovs, Ellen M Ross, Frank Heuts, Yassin Elfaki, Luke P Houghton, Toby Talbot, Amna Sheri, Alexandra Pender, David Chao, Lucy S K Walker. Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. Immunotherapy advances. 2023, 3 (1): ltad001Cited : 3Read More
- 4)- . Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunotherapy advances. 2023, 3 (1): ltad002Cited : 0Read More
- 5)- . Correction to: Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy advances. 2023, 3 (1): ltad003Cited : 0Read More
- 6)- . Correction to: Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity. Immunotherapy advances. 2023, 3 (1): ltad004Cited : 0Read More
- 7)- Paul R Buckley, Chloe H Lee, Agne Antanaviciute, Alison Simmons, Hashem Koohy. A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. Immunotherapy advances. 2023, 3 (1): ltad005Cited : 3Read More
- 8)- Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi. Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances. 2023, 3 (1): ltad006Cited : 2Read More
- 9)- Shimon Sakaguchi, Ryoji Kawakami, Norihisa Mikami. Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective. Immunotherapy advances. 2023, 3 (1): ltad007Cited : 4Read More
- 10)- Megan Sykes. Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity. Immunotherapy advances. 2023, 3 (1): ltad008Cited : 0Read More
- 11)- Akshay J Patel, Gary W Middleton. TIGIT-based immunotherapeutics in lung cancer. Immunotherapy advances. 2023, 3 (1): ltad009Cited : 2Read More
- 12)- Andrew Abaasa, Moses Egesa, Emmanuella Driciru, Jan Pieter R Koopman, Ronald Kiyemba, Richard E Sanya, Jacent Nassuuna, Agnes Ssali, Geofrey Kimbugwe, Anne Wajja, Govert J van Dam, Paul L A M Corstjens, Stephen Cose, Janet Seeley, Dorcas Kamuya, Emily L Webb, Maria Yazdanbakhsh, Pontiano Kaleebu, Afzal A Siddiqui, Narcis Kabatereine, Edridah Tukahebwa, Meta Roestenberg, Alison M Elliott. Establishing a single-sex controlled human infection model for Uganda: protocol for safety and dose-finding trial. Immunotherapy advances. 2023, 3 (1): ltad010Cited : 1Read More
- 13)- Michael J Walsh, Lestat R Ali, Patrick Lenehan, Courtney T Kureshi, Rakeeb Kureshi, Michael Dougan, David M Knipe, Stephanie K Dougan. Blockade of innate inflammatory cytokines TNF, IL-1, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunotherapy advances. 2023, 3 (1): ltad011Cited : 2Read More
- 14)- María José Mansilla, Catharien M U Hilkens, Eva M Martínez-Cáceres. Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. Immunotherapy advances. 2023, 3 (1): ltad012Cited : 6Read More
- 15)- Winston M Zhu, Mark R Middleton. Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. Immunotherapy advances. 2023, 3 (1): ltad013Cited : 5Read More
- 16)- Walter Bodmer. A historical perspective on HLA. Immunotherapy advances. 2023, 3 (1): ltad014Cited : 1Read More
- 17)- Meiyin Lin, Sebastian Chakrit Bhakdi, Damien Tan, Joycelyn Jie Xin Lee, David Wai Meng Tai, Andrea Pavesi, Lu-En Wai, Tina Wang, Antonio Bertoletti, Anthony Tanoto Tan. Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. Immunotherapy advances. 2023, 3 (1): ltad015Cited : 1Read More
- 18)- Lars Klareskog, Lars Alfredsson. Prevention vs treatment of rheumatoid arthritis. Immunotherapy advances. 2023, 3 (1): ltad016Cited : 1Read More
- 19)- . Correction to: Immunology of allergen immunotherapy. Immunotherapy advances. 2023, 3 (1): ltad017Cited : 0Read More
- 20)- . Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition? Immunotherapy advances. 2023, 3 (1): ltad018Cited : 0Read More
- 21)- . Correction to: Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunotherapy advances. 2023, 3 (1): ltad019Cited : 0Read More
- 22)- Melissa M Christodoulidou, Neil A Mabbott. Efficacy of smallpox vaccines against Mpox infections in humans. Immunotherapy advances. 2023, 3 (1): ltad020Cited : 3Read More
- 23)- Patrícia Silva Santos Ribeiro, Hanneke L D M Willemen, Sabine Versteeg, Christian Martin Gil, Niels Eijkelkamp. NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain. Immunotherapy advances. 2023, 3 (1): ltad022Cited : 1Read More
- 24)- Ester Gea-Mallorquí, Sarah Rowland-Jones. DC-targeting lentivectors for cancer immunotherapy. Immunotherapy advances. 2023, 3 (1): ltad023Cited : 0Read More
- 25)- Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw, . Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunotherapy advances. 2023, 3 (1): ltad024Cited : 1Read More
- 26)- Sandra Kleinau. Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma. Immunotherapy advances. 2023, 3 (1): ltad025Cited : 0Read More
- 27)- Katie R Flaherty, Stephanie Kucykowicz, Johannes Schroth, Will Traves, Kyle T Mincham, George E Finney. Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key? Immunotherapy advances. 2023, 3 (1): ltad026Cited : 0Read More
